Our data suggested that SGLT2 inhibition was not renoprotective in women with PCOS, even though we saw a small decrease in MAP that was also reported with SGLT2 inhibition in T2DM [16,19,21]. Here, SLC5A2 is linked to polycystic ovary syndrome.